Sagimet Biosciences

formerly Sagimet Biosciences Inc. Series AIPO

Sagimet Biosciences is a biotech company in San Mateo, United States, founded in 2006. It has raised $153.5M across 4 rounds, most recently an $80.0M Growth Equity in February 2021.

Advancing FASN Inhibitors for Metabolic Disease

Employees
11–50
Founded
2006
Business Model
B2B
Total Funding
$153.5M
Last Round
$80.0M Growth EquityFeb 2021
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 7 investors for this company. The full record is or through the API.

About

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways caused by overproduction of the fatty acid palmitate. FASN regulates lipid synthesis and is implicated in acne, metabolic dysfunction-associated steatohepatitis (MASH), and certain FASN-dependent tumors. Lead candidate denifanstat is an oral FASN inhibitor with a Phase 3-ready MASH program and additional dermatology and oncology development, including the topical FASN inhibitor TVB-3567.

Summary

It lists 11–50 employees. It has raised $153.5M in total across 4 rounds, most recently a $80.0M Growth Equity round in Feb 2021. Investors include Ascletis, Kleiner Perkins and New Enterprise Associates.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
IPOJul 2023
$85.0M

Sign up to see all 5 events

Funding: Series C through Growth Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Sagimet Biosciences on Indexed.vc
<a href="https://indexed.vc/companies/sagimet-biosciences"><img src="https://indexed.vc/api/badge/company/sagimet-biosciences" alt="Sagimet Biosciences on Indexed.vc" width="260" height="76" /></a>